Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 1:04 p.m.

    📋 GRI BIO, INC. (GRI) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:01:16

    Event Type: Clinical Trial Update

    Event Details:

    GRI Bio Inc (GRI) Announces Clinical Trial Update GRI Bio Inc (GRI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: modulators, Study
    • Diseases/Conditions: Idiopathic Pulmonary Fibrosis
    • Clinical Stage: clinical trial
    • Collaboration: BAL

    🔬 Clinical Development Pipeline (GRI BIO, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Tazarotene (GRI-0621) DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: GRI Bio Inc
    • CIK: 0001824293
    • Ticker Symbol: GRI
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories